David R. Bauer
Lawyers
Filters
Gamida Cell Ltd. $35 Million Follow-On Offering
Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq…
The Medicines Company $172.5 Million Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by The Medicines Company of 5,227,273 shares of common stock for approximately $172.5 million, which…
Personalis, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million initial public offering by Personalis, Inc. The common stock is listed…
Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…
Orchard Therapeutics plc Approximately $128 Million Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics…
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied…
Intercept Pharmaceuticals, Inc. Concurrent $231 Million Common Stock Offering and $230 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc. …
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…
Magenta Therapeutics, Inc. $64.8 Million Follow-On Offering of Common Stock
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics,…
TransMedics Group, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…